Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.085 AUD
−12.24 M AUD
91.65 M AUD
172.49 M
About SOMNOMED LIMITED
Sector
Industry
Headquarters
Sydney
Website
Founded
1987
ISIN
AU000000SOM1
FIGI
BBG000Q6QG76
SomnoMed Ltd. engages in the production and sale of devices for the oral treatment of sleep related disorders. Its products include SomnoDent, SomMorning Repositioner, SomnoBrux, SomTabs, and Sunrise Sleep Test. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded in 2004 and is headquartered in Sydney, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SOM is 0.285 AUD — it hasn't changed in the past 24 hours. Watch SOMNOMED LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange SOMNOMED LIMITED stocks are traded under the ticker SOM.
SOM stock has fallen by −8.06% compared to the previous week, the month change is a −14.93% fall, over the last year SOMNOMED LIMITED has showed a −24.84% decrease.
We've gathered analysts' opinions on SOMNOMED LIMITED future price: according to them, SOM price has a max estimate of 0.42 AUD and a min estimate of 0.42 AUD. Watch SOM chart and read a more detailed SOMNOMED LIMITED stock forecast: see what analysts think of SOMNOMED LIMITED and suggest that you do with its stocks.
SOM stock is 0.00% volatile and has beta coefficient of 0.86. Track SOMNOMED LIMITED stock price on the chart and check out the list of the most volatile stocks — is SOMNOMED LIMITED there?
Yes, you can track SOMNOMED LIMITED financials in yearly and quarterly reports right on TradingView.
SOMNOMED LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
SOM earnings for the last half-year are −0.01 AUD per share, whereas the estimation was 0.00 AUD, resulting in a −133.33% surprise. The estimated earnings for the next half-year are 0.00 AUD per share. See more details about SOMNOMED LIMITED earnings.
SOMNOMED LIMITED revenue for the last half-year amounts to 46.50 M AUD, despite the estimated figure of 46.50 M AUD. In the next half-year revenue is expected to reach 48.00 M AUD.
SOM net income for the last half-year is −5.89 M AUD, while the previous report showed −6.35 M AUD of net income which accounts for 7.13% change. Track more SOMNOMED LIMITED financial stats to get the full picture.
No, SOM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOMNOMED LIMITED EBITDA is −2.99 M AUD, and current EBITDA margin is −2.77%. See more stats in SOMNOMED LIMITED financial statements.
Like other stocks, SOM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOMNOMED LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOMNOMED LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOMNOMED LIMITED stock shows the sell signal. See more of SOMNOMED LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.